MOLBIO DIAGNOSTICS LIMITED

BSE: MOLBIO544866ISIN INE869T01028

Healthcare
Medical Equipment & Supplies
BSE IPO

Share price

₹1,274.65-28.90 (-2.22%)

as of 30 Oct 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,686.50
52W low: ₹925.80
Off 52W high: -24.42%
1M return: -2.66%
3M return: —
6M return: —
1Y return: —
20D avg volume: 2,15,032
50 DMA: ₹1,289.54
200 DMA: —

Key ratios Consolidated

Market cap: ₹14,689 Cr
Current price: ₹1,274.65
52W high / low: ₹1,686.50 / ₹925.80
Face value: ₹1.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: —
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: —
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: —

Financials

Metric	Q1 FY27
Income statement
	408.38
	3.10
	411.48
	335.57
	131.47
	6.26
	45.92
	10.70
	17.07
	112.19
	75.91
	0.00
	75.91
	23.16
	52.74
	5.21
Key metrics
	103.68
	25.40%
	12.90%

Metric	Q1 FY27
Income statement
	399.38
	1.37
	400.75
	324.82
	126.72
	6.09
	24.76
	8.66
	8.42
	138.74
	75.92
	0.00
	75.92
	19.30
	56.63
	5.02
Key metrics
	93.00
	23.30%
	14.20%

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 41.29%

Quarter	September 2026	14 Aug 2026
Promoter %	41.29%	41.29%

Holder	Type	Holding	Previous	Change
EXXORA TRADING LLP	Promoter	37.05%	37.05%	0.00%
BUSINESS EXCELLENCE TRUST III - INDIA BUSINESS EXC	Public	8.92%	11.52%	-2.60%
V-SCIENCES INVESTMENTS PTE LTD	Public	8.74%	8.74%	0.00%
KINI GOPALKRISHNA MANGALORE	Public	5.61%	—	—
KOTAK AGGRESSIVE HYBRID FUND	Public	4.99%	—	—
GOPALAKRISHNA SAMPATHGIRI	Public	4.52%	4.52%	0.00%
JAVAGAL GURU DUTT	Public	4.48%	4.48%	0.00%
Chandrasekhar Bhaskaran Nair	Promoter	4.24%	4.24%	0.00%
USHA RANI M A	Public	2.45%	2.45%	0.00%
SANGEETHA MANGALORE KINI	Public	2.26%	2.26%	0.00%
ROHIT MULLANGI ASHOK KUMAR	Public	1.45%	1.45%	0.00%
SHRUTHI G KINI	Public	1.09%	1.09%	0.00%
Tripti Pissurlencar	Promoter Group	0.00%	0.00%	0.00%
Kallows Engineering India Private Limited	Promoter Group	0.00%	0.00%	0.00%
Anita A Chandrasekhar	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
MOLBIO DIAGNOSTICS LIMITED	14,689	1,274.65	—	—	—	—	—
Poly Medicure Ltd	14,676	1,447.90	46.90	13.20%	+18.31% TTM	-12.49% TTM	-26.67%
Sahajanand Medical Technologies Limited	4,675	459.95	—	—	—	—	—
FISCHER MEDICAL VENTURES LIMITED	1,620	24.75	58.02	12.70%	+195.94% TTM	+371.52% TTM	-78.93%
Tarsons Products Limited	1,552	291.75	139.91	4.80%	+10.63% TTM	-59.68% TTM	+0.67%
Laxmi Dental Limited	978	177.75	31.65	11.50%	—	—	-43.88%
Hemant Surgical Industries Limited	834	573.60	—	19.50%	—	—	+99.17%
Fabtech Technologies Limited	547	123.00	15.35	11.60%	—	—	-47.33%
Prevest Denpro Limited	452	376.35	—	21.90%	—	—	-29.35%
Nureca Limited	285	298.80	59.89	3.40%	+33.66% TTM	+15.82% TTM	+11.18%
EARKART LIMITED S	160	116.00	32.31	12.10%	—	—	-47.01%
CHOKSI ASIA LIMITED S	121	212.95	23.40	18.40%	+21.40% TTM	+132.74% TTM	+106.21%
Shree Pacetronix Ltd	63	169.00	19.58	25.00%	+22.63% TTM	+208.57% TTM	-36.23%
Amkay Products Limited S	46	53.00	19.85	13.40%	—	—	+20.70%
KMS Medisurgi Limited S	44	132.80	177.07	4.80%	—	—	—
Royal Sense Limited	40	74.00	—	26.10%	—	—	-67.97%
GKB Ophthalmics Ltd.	30	59.00	5.39	9.60%	+29.95% TTM	+170.50% TTM	-11.45%
Centenial Surgical Suture Ltd. S	26	71.25	-17.99	2.60%	+6.70% TTM	+26.29% TTM	-33.32%
Transpact Enterprises Limited S	4	100.70	—	14.50%	—	—	-57.35%

Some figures use IPO-document inputs. Growth periods are shown per value; FY means annual.

Filings & corporate actions

Recent announcements

Clarification on Spurt in Volume of shares of the Company.19 Oct 2026 · Company Update / General
The Exchange has sought clarification from Molbio Diagnostics Ltd on October 19, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.19 Oct 2026 · Company Update / Clarification
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kotak Mahindra Mutual Fund16 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kotak Mahindra Mutual Fund13 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Certificate under Regulation 74(5) of the SEBI(Depositories and Participants)Regulations, 2018 for the quarter ended September 30,2026.8 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III,1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation of Closure of Trading Window for the Quarter ended September 30,2026.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of re-appointment of Cost Auditor of the Company pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.25 Sep 2026 · Others / Outcome without intimation
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III25 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III25 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III24 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation of Analysts/Investors Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, scheduled to be held on Tuesday, September ....17 Sep 2026 · Company Update / Analyst / Investor Meet
Pursuant to Regulation 30 of the SEBI(LODR),2015, Please find attached herewith the Transcripts of the Earning call held on September 08,2026 in relation to the Fianncial Results for the ....12 Sep 2026 · Company Update / Earnings Call Transcript
Intimation of Change of Corporate Identification Number (CIN) of the company.9 Sep 2026 · Company Update / General
Audio Recording of Earnings Call for the quarter ended June 30, 2026.8 Sep 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.8 Sep 2026 · Company Update / Investor Presentation
Newspaper advertisments of Un-Audited Financials Results for the quarter ended June 30, 2026.7 Sep 2026 · Company Update / Newspaper Publication
Molbio Diagnostics Limited has informed the Exchange regarding the Press Release for the Quarter ended June 30,2026.7 Sep 2026 · Company Update / Press Release / Media Release
The Board of Directors at their meeting held on Saturday, September 05, 2026 approved the Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30, 20265 Sep 2026 · Board Meeting / Outcome of Board Meeting
Outcome of the Board Meeting held on Saturday, September 05,2026.5 Sep 2026 · Result / Financial Results
Intimation of Earnings Conference Call under Regulation 30 and all other applicable regulations, if any, of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) ....2 Sep 2026 · Company Update / Analyst / Investor Meet
Molbio Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2026 ,inter alia, to consider and approve To consider and approve ....1 Sep 2026 · Board Meeting / Board Meeting
Outcome of Board Meeting held on August 27, 2026, as per Reg 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').27 Aug 2026 · Others / Outcome without intimation
Intimation of Closure Trading Window as per SEBI (Prohibition of Insider Trading) Regulations, 201520 Aug 2026 · Insider Trading / SAST / Closure of Trading Window
Trading Members of the Exchange are hereby informed that effective from August 17, 2026, the Equity Shares of Molbio Diagnostics Ltd (Scrip Code: 544866) are listed and admitted to dealings ....17 Aug 2026 · New Listing / New Listing

Board meetings

5 Sep 2026 Board Meeting - Financial Results